Bulk Pharmaceutical API Sources for SULFADIAZINE SODIUM

Bulk Pharmaceutical API Sources for SULFADIAZINE SODIUM

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-927-096
Amadis Chemical		A830351
AKos Consulting & Solutions		AKOS024430976
AKos Consulting & Solutions		AKOS025310751
BOC Sciences		547-32-0
Glentham Life Sciences Ltd.		GA7306
Sigma-Aldrich		S6387_SIAL

Bulk Active Pharmaceutical Ingredient (API) Sources for Sulfadiazine Sodium

Last updated: July 27, 2025

Introduction

Sulfadiazine sodium, a water-soluble sulfonamide antibiotic, plays a pivotal role in treating bacterial infections, particularly in veterinary medicine and certain human applications. As a key pharmaceutical compound, the sourcing of bulk active ingredients (APIs) like sulfadiazine sodium is crucial for pharmaceutical manufacturers aiming for quality, affordability, and supply chain reliability. This report examines current bulk API sources for sulfadiazine sodium, evaluates global supplier landscapes, and offers insights on procurement strategies for pharmaceutical companies.

Regulatory Framework and Industry Standards

Sourcing APIs such as sulfadiazine sodium necessitates compliance with stringent regulatory standards, including Good Manufacturing Practices (GMP) stipulated by agencies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and regulations under the World Health Organization (WHO) prequalification program. Suppliers must demonstrate product purity, consistent quality, and traceability to meet these standards, especially for manufacturing pharmaceuticals intended for human use.

Global API Manufacturing and Supply Landscape

Major Manufacturing Regions

API manufacturing for sulfadiazine sodium predominantly occurs in regions renowned for bulk chemical production:

• India: India remains the largest supplier of generic APIs, including sulfonamides. Indian API manufacturers benefit from cost-effective production, established export infrastructure, and compliance with international quality standards. Companies such as Hetero Drugs, Granules India, and Cadila Healthcare offer sulfadiazine sodium API with GMP certification.
• China: Chinese chemical manufacturers have scaled API production, often producing at competitive prices. Many Chinese suppliers possess ISO, WHO GMP, and other certifications suitable for export to regulated markets. Leading firms include North China Pharmaceutical Group (NCPC) and Zhejiang Jiuzhou Pharmaceutical.
• Europe and North America: While these regions traditionally focus on drug substance development and finished dosage forms, a limited number of high-quality API producers exist to serve specialized markets. Companies like Evonik and Allergan (now part of AbbVie) manufacture APIs adhering to rigorous regulatory standards, though their focus on sulfadiazine sodium is less prominent than other regions.

API Manufacturers of Sulfadiazine Sodium

Sulfadiazine sodium is produced by a limited but notable group of specialized chemical manufacturers, often providing bulk APIs to pharmaceutical firms globally:

1. Hetero Drugs (India): Offers sulfadiazine sodium API conforming to GMP standards, with a focus on quality and reliable supply.
2. Granules India (India): Provides a range of sulfonamide APIs, including sulfadiazine sodium, with ISO and GMP certifications.
3. North China Pharmaceutical Group Corporation (NCPC, China): Supplies sulfadiazine sodium with a focus on bulk quantities and compliance with international standards.
4. Zhejiang Jiuzhou Pharmaceutical (China): Produces APIs for antibiotics, including sulfadiazine sodium, emphasizing quality control and global export capabilities.
5. Sino Biopharmaceutical (China): Engages in the manufacturing of sulfonamide APIs and serves as a strategic supplier for some global pharmaceutical companies.

Secondary Suppliers and Contract Manufacturing Organizations (CMOs)

Due to rising demand, several contract manufacturing organizations have tailored production capabilities for sulfadiazine sodium, often offering custom synthesis, quality assurance, and regulatory support. CMOs provide an alternative for pharmaceutical firms seeking flexible sourcing options without establishing in-house manufacturing.

Supplier Selection Criteria

When sourcing sulfadiazine sodium APIs, pharmaceutical companies should prioritize:

• Regulatory Compliance: GMP certification, DEA approvals (if applicable), and adherence to international standards (e.g., ISO, WHO PQ).
• Quality Assurance: Batch-to-batch consistency, analytical method validation, and impurity profiles.
• Supply Chain Reliability: Proven track record of on-time delivery, capacity to scale, and transparent logistics.
• Pricing and Lead Times: Competitive pricing aligned with market norms, alongside reasonable lead times.
• Traceability and Documentation: Comprehensive documentation, including Certificates of Analysis (COA), stability data, and manufacturing licenses.

Emerging Trends and Market Dynamics

Regulatory Stringency and Quality Expectations

The increasing stringency of global pharmaceutical regulations pressures suppliers to maintain high-quality production standards—a key factor for companies intending to market sulfadiazine sodium API in developed markets. Suppliers often undergo rigorous audits and validation processes.

Supply Chain Diversification

Global disruptions, such as the COVID-19 pandemic and geopolitical tensions, have heightened awareness about supply chain vulnerabilities. Pharmaceutical firms are diversifying API sourcing among multiple suppliers and regions, encouraging competition and ensuring consistent supply.

Sustainability and Ethical Sourcing

Environmental and social considerations influence sourcing decisions. Suppliers investing in environmentally friendly manufacturing processes and sustainable practices are gaining favor in the market.

Challenges in API Sourcing

• Quality Variability: Variations in impurity profiles and batch consistency among suppliers can impact drug safety and efficacy.
• Intellectual Property Rights: Though APIs like sulfadiazine sodium are generally off-patent, licensing agreements may be necessary for certain formulations.
• Regulatory Acceptance: Not all suppliers' products meet regulatory standards across jurisdictions, requiring due diligence and validation.

Conclusion

The global market for sulfadiazine sodium API is primarily dominated by Indian and Chinese manufacturers, offering cost-effective and scalable options. US, European, and other highly regulated markets rely on GMP-accredited suppliers capable of meeting rigorous standards. Strategic sourcing from qualified, certified suppliers ensures quality, supply continuity, and regulatory compliance.

Pharmaceutical firms should emphasize robust supplier qualification processes, diversify sourcing strategies, and incorporate sustainability considerations to strengthen their supply chains. As regulatory landscapes evolve and demand for high-quality APIs increases, maintaining transparent, compliant partnerships remains critical.

---

Key Takeaways

• Indian and Chinese manufacturers are leading sulfadiazine sodium API suppliers, characterized by cost-effectiveness and substantial production capacity.
• Regulatory compliance, GMP certification, and consistent quality are essential criteria when selecting API suppliers.
• Emerging supply chain disruptions have encouraged diversification and increased scrutiny of supplier reliability.
• Contract manufacturing organizations (CMOs) offer flexible sourcing options for pharmaceutical companies seeking tailored solutions.
• Sustainability and ethical manufacturing practices are increasingly influencing procurement decisions within the API supply chain.

---

FAQs

1. What are the primary regions manufacturing sulfadiazine sodium API?
   India and China dominate sulfadiazine sodium API production, with several GMP-certified suppliers in these regions. Europe and North America have fewer producers focused on regulated markets.

2. How can pharmaceutical companies ensure API quality compliance?
   By verifying suppliers’ GMP certification, reviewing Certificates of Analysis, conducting audits, and ensuring batch validation adherence to quality standards.

3. Are there alternative suppliers to Indian and Chinese manufacturers?
   Yes. Some European and North American firms produce sulfadiazine sodium APIs, often catering to high-regulatory standards, though they may offer higher pricing.

4. What factors influence API sourcing in the current market?
   Quality assurance, regulatory compliance, supply chain reliability, pricing, and sustainability considerations are key factors.

5. How does regulatory compliance impact API sourcing?
   Suppliers must meet international standards (GMP, ISO), especially for APIs used in human pharmaceuticals. Non-compliance can lead to regulatory rejection or post-market actions.

---

References

[1] U.S. FDA Drug Master Files, 2023.
[2] WHO Prequalification Programme, API Standards, 2022.
[3] Indian Pharmacopoeia and manufacturing certifications.
[4] Chinese Pharmacopoeia and GMP guidelines, 2022.
[5] Industry market reports, IQVIA and GlobalData, 2023.